A Study on the Improvement of Postoperative Symptoms and Survival Benefits of Modified Bufei Decoction in Elderly Patients With Lung Cancer Undergoing Radical Surgery
Recruiting · NCT06674252 · Interventional (participants receive a specific treatment) · Lead sponsor: Peking University Cancer Hospital & Institute
View the official record on ClinicalTrials.gov →Interventions studied
What this trial is about
This is a randomized double-blind placebo-controlled phase II clinical study that included patients with symptoms such as cough, shortness of breath, and fatigue after lung cancer resection surgery. They were given orally modified Bufei Tang granules twice a day for 28 days, with one packet taken orally with water. Using the MDASI-TCM symptom scoring system, evaluate the scores of symptoms such as cough, shortness of breath, and fatigue before and after the experiment, and calculate the difference in scores between the control group and the experimental group before and after the experiment.
Who can take part
Inclusion criteria
- Patients with postoperative lung cancer who have clear histological or cytological diagnosis.
- Age ≥ 65 years old, both male and female are eligible. According to the MDASI-TCM scale evaluation, any of the three symptoms of cough, fatigue, and shortness of breath should score ≥ 4 points, or the sum of the three should score ≥ 6 points.
- The heart function is basically normal; ALT/AST is within 2 times the normal value; SCr is within the normal range.
- Traditional Chinese medicine syndrome differentiation is characterized by deficiency of both lungs and kidneys.
Exclusion criteria
- Patients with severe pulmonary infections. ⑵. Patients with mental illness. ⑶. Patients with depression.
Where it is running
2 locations listed.
- Beijing cancer hospital - Beijing, Beijing Municipality, China
- Beijing cancer hospital - Beijing, Beijing Municipality, China